New horizons of methotrexate application
暂无分享,去创建一个
S. Vukmirović | M. Mikov | S. Goločorbin-Kon | Vladimir Maksimovic | Z. Pavlović-Popović | J. Cvejić
[1] Yong-Bok Lee,et al. Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery , 2019, International journal of molecular sciences.
[2] H. Al‐Salami,et al. Environmental Transformation of Pharmaceutical Formulations: A Scientific Review , 2019, Archives of Environmental Contamination and Toxicology.
[3] Min-yan Wei,et al. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery , 2019, Pharmaceutics.
[4] R. Löbenberg,et al. Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug. , 2017, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[5] S. Youn,et al. Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All? , 2017, Annals of dermatology.
[6] S. Teimourian,et al. An Overview of Inflammatory Bowel Disease: General Consideration and Genetic Screening Approach in Diagnosis of Early Onset Subsets , 2017, Middle East journal of digestive diseases.
[7] M. Gremião,et al. Bioadhesive Surfactant Systems for Methotrexate Skin Delivery , 2016, Molecules.
[8] H. Herfarth,et al. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases , 2016, Inflammatory bowel diseases.
[9] Meliha Ekinci,et al. Methotrexate loaded chitosan nanoparticles: Preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis , 2015 .
[10] R. Neubert,et al. Methotrexate for topical application in an extemporaneous preparation , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[11] Ahmed Abdelbary,et al. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. , 2015, International journal of pharmaceutics.
[12] C. Nunes,et al. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. , 2014, International journal of pharmaceutics.
[13] R. Giacomelli,et al. Methotrexate: an old new drug in autoimmune disease , 2014, Expert review of clinical immunology.
[14] H. Al‐Salami,et al. Inflammatory bowel disease: clinical aspects and treatments , 2014, Journal of inflammation research.
[15] B. Cronstein,et al. Regulation of Inflammation by Adenosine , 2013, Front. Immunol..
[16] S. Arora,et al. Formulation and In Vitro Evaluation of Ufasomes for Dermal Administration of Methotrexate , 2012, ISRN pharmaceutics.
[17] I. Tucker,et al. Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. , 2009, Journal of pharmaceutical and biomedical analysis.
[18] B. Cronstein,et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. , 2007, Arthritis and rheumatism.
[19] E. Lower,et al. A clinical approach to the use of methotrexate for sarcoidosis , 1999, Thorax.
[20] B. Liagre,et al. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. , 1998, The Journal of rheumatology.
[21] M. Weinblatt,et al. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. , 1992, Arthritis and rheumatism.
[22] M. Hicks,et al. Ufasomes are Stable Particles surrounded by Unsaturated Fatty Acid Membranes , 1973, Nature.
[23] H. Al‐Salami,et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. , 2019, Technology and health care : official journal of the European Society for Engineering and Medicine.
[24] Rana Jahanban-Esfahlan,et al. New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[25] M. Weinblatt. Methotrexate in rheumatoid arthritis: a quarter century of development. , 2013, Transactions of the American Clinical and Climatological Association.
[26] J. Neradil,et al. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.
[27] I. Tucker,et al. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. , 2009, The Journal of pharmacy and pharmacology.
[28] M. Iannuzzi,et al. The Diagnosis and Management of Sarcoidosis , 2006 .